We are live on
!
Find out more
EAM
Exome Asset Management Portfolio holdings
AUM
$193M
1-Year Est. Return
208.51%
This Fund
S&P 500
This Quarter
Est. Return
+33.89%
1 Year Est. Return
+208.51%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$165M
AUM Growth
+$30.6M
(+23%)
Cap. Flow
+$8.38M
Cap. Flow
% of AUM
5.07%
Top 10 Holdings %
Top 10 Hldgs %
37.21%
Holding
97
New
34
Increased
10
Reduced
12
Closed
29
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
MoonLake Immunotherapeutics
MLTX
|
+$9.28M |
| 2 |
NBP
NovaBridge Biosciences American Depositary Shares
NBP
|
+$4.89M |
| 3 |
Apogee Therapeutics
APGE
|
+$3.6M |
| 4 |
CVS Health
CVS
|
+$2.99M |
| 5 |
AKRO
Akero Therapeutics
AKRO
|
+$2.84M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Scholar Rock
SRRK
|
+$2.99M |
| 2 |
Fulcrum Therapeutics
FULC
|
+$2.5M |
| 3 |
Syndax Pharmaceuticals
SNDX
|
+$2.49M |
| 4 |
Verastem
VSTM
|
+$2.49M |
| 5 |
Geron
GERN
|
+$2.07M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 89.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
CALL
Travere Therapeutics
TVTX
$5.33B
| $2.63M | 1.59% |
110,000
| – | – |
|
27
Immunovant
IMVT
$8.11B
| $2.56M | 1.55% |
+158,622
| New | +$2.57M |
|
|
28
Geron
GERN
$860M
| $2.55M | 1.54% |
1,858,354
-1,556,023
| -46% | -$2.07M |
|
29
CytomX Therapeutics
CTMX
$714M
| $2.38M | 1.44% |
+745,305
| New | +$1.68M |
|
30
Penumbra
PEN
$12.6B
| $2.28M | 1.38% |
9,000
| – | – |
|
31
Glaukos
GKOS
$9.9B
| $2.21M | 1.34% |
+27,143
| New | +$2.49M |
|
32
Liquidia Corp
LQDA
$7.72B
| $2.14M | 1.3% |
94,235
+73,735
| +360% | +$1.6M |
|
|
CNTA
33
DELISTED
Centessa Pharmaceuticals
CNTA
| $2.13M | 1.29% |
88,024
-78,920
| -47% | -$1.4M |
|
|
NVO
34
CALL
Novo Nordisk
NVO
$228B
| $1.94M | 1.18% |
+35,000
| New | +$2.05M |
|
35
10x Genomics
TXG
$6.28B
| $1.91M | 1.16% |
163,658
| – | – |
|
36
Cencora
COR
$60.7B
| $1.88M | 1.14% |
+6,000
| New | +$1.77M |
|
|
37
Syndax Pharmaceuticals
SNDX
$1.73B
| $1.81M | 1.1% |
117,783
-190,515
| -62% | -$2.49M |
|
|
WAY
38
Waystar Holding Corp
WAY
$4.02B
| $1.78M | 1.08% |
46,900
| – | – |
|
39
Universal Health Services
UHS
$9.88B
| $1.63M | 0.98% |
7,955
-2,145
| -21% | -$386K |
|
40
Oric Pharmaceuticals
ORIC
$1.2B
| $1.45M | 0.88% |
+120,644
| New | +$1.27M |
|
41
Procept Biorobotics
PRCT
$1.02B
| $1.42M | 0.86% |
+39,900
| New | +$1.82M |
|
42
Inspire Medical Systems
INSP
$1.44B
| $1.38M | 0.84% |
+18,600
| New | +$1.88M |
|
43
uniQure
QURE
$2.93B
| $1.29M | 0.78% |
+22,090
| New | +$401K |
|
|
44
MoonLake Immunotherapeutics
MLTX
$1.62B
| $1.28M | 0.77% |
+178,084
| New | +$9.28M |
|
45
Avalo Therapeutics
AVTX
$1.03B
| $1.27M | 0.77% |
+100,036
| New | +$860K |
|
|
46
PUT
Liquidia Corp
LQDA
$7.72B
| $1.21M | 0.73% |
+53,000
| New | +$1.15M |
|
47
Gossamer Bio
GOSS
$87.2M
| $1.19M | 0.72% |
451,699
-646,300
| -59% | -$1.42M |
|
|
ALMS
48
Alumis Inc
ALMS
$3.69B
| $1.17M | 0.71% |
+292,770
| New | +$1.21M |
|
|
UPB
49
Upstream Bio Inc
UPB
$358M
| $977K | 0.59% |
+51,960
| New | +$807K |
|
50
PUT
Arcturus Therapeutics
ARCT
$168M
| $922K | 0.56% |
+50,000
| New | +$803K |
|
Similar funds
WWC
JHA
TDWM
DF
SCM
PA
SCPM
EWM
Exome Asset Management's Q3 2025 Portfolio in Review
As of Q3 2025, Exome Asset Management held 97 positions worth $165M, up 23% from $135M the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Exome Asset Management deployed $8.38M of net new capital in Q3 2025, opening 34 new positions and adding to 10 existing holdings. Its largest new stake was MoonLake Immunotherapeutics: 178,084 shares worth $1.28M.
By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 80% a quarter earlier.
On the sell side, the largest reduction was Fulcrum Therapeutics, an estimated $2.5M trimmed.
- Exome Asset Management's largest Q3 2025 buy was MoonLake Immunotherapeutics: 178,084 shares worth $1.28M.
- Exome Asset Management added most to Eli Lilly in Q3 2025, an estimated $2.37M increase.
- Exome Asset Management's biggest Q3 2025 reduction was Fulcrum Therapeutics, cutting an estimated $2.5M.
- Exome Asset Management fully exited Scholar Rock in Q3 2025, selling an estimated $2.99M.
- Exome Asset Management's ten largest holdings make up 37% of its $165M portfolio in Q3 2025.
- Exome Asset Management opened 34 new positions and closed 29 in Q3 2025.
- Exome Asset Management's portfolio value rose 23% quarter-over-quarter to $165M.
Based on Exome Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.